Frontier Biotechnologies(SH:688221) Sou Hu Cai Jing·2025-07-29 10:37Core Insights - Frontier Biopharmaceuticals (688221) reported a closing price of 22.42 yuan as of July 29, 2025, reflecting a 9.74% increase with a turnover rate of 12.58% and a trading volume of 471,400 lots, amounting to 1.023 billion yuan in transaction value [1] Financial Performance - For the first quarter of 2025, the company achieved total operating revenue of 28.3282 million yuan, representing a year-on-year growth of 14.93% - The net profit attributable to shareholders was 44.1215 million yuan, up 20.80% year-on-year - The net profit after deducting non-recurring gains and losses was 53.1457 million yuan, an increase of 15.22% year-on-year - The current ratio stood at 2.721, the quick ratio at 2.612, and the debt-to-asset ratio at 36.35% [1] Capital Flow - On the trading day, the net inflow of main funds was 63.2741 million yuan, accounting for 6.19% of the transaction value - Large orders saw a net inflow of 33.4589 million yuan, representing 3.27% of the transaction value, while small orders experienced a net outflow of 68.8571 million yuan, which is 6.73% of the transaction value [1] Company Overview - Frontier Biopharmaceuticals (Nanjing) Co., Ltd. was established in 2013 and is located in Nanjing, primarily engaged in the pharmaceutical manufacturing industry - The company has a registered capital of 3.74578653 billion yuan and a paid-in capital of 1.75 billion yuan - The legal representative of the company is Dong Xie [1][2] Investment and Intellectual Property - The company has made investments in 8 enterprises and participated in 29 bidding projects - It holds 30 trademark registrations and 20 patent registrations, along with 121 administrative licenses [2]